Security
NeuroOne Medical Technologies Corporation Common Stock · NMTC
NMTCNASDAQCommon stockCurrentCIK 1500198Updated Oct 6, 2026
Name history
Original Source Entertainment, Inc. · through May 22, 2017
NMTC price & chart
Loading TradingView…
NASDAQ:NMTC on TradingView ↗About the company
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.
In the news
No coverage from other publishers is available.
Recent filings
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by Pratt Brian regarding NEUROONE MEDICAL TECHNOLOGIES Corp
Show 5 more recent filings
3 filing
424B5 filing
Other Events
Items 8.01, 9.01
10-Q/A filing
SD filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,785,647Source | 5,369,940Source | 8,097,314Source | 12,822,609Source |
| Property, Plant and Equipment, NetUSD | 259,222Source | 416,843Source | 525,753Source | 353,599Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 44,946Source | 67,262Source | 89,577Source | 111,892Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,570,382Source | 1,460,042Source | 5,322,493Source | 8,160,329Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,264,805Source | 176,636Source | — | 33,237Source |
| Inventory, NetUSD | 2,226,805Source | 2,635,153Source | 1,726,686Source | 704,538Source |
| Assets, CurrentUSD | 10,226,284Source | 4,630,925Source | 7,312,925Source | 12,175,763Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 216,461Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 255,195Source | 254,910Source | 169,059Source | 181,355Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,713,125Source | 4,547,927Source | 1,847,910Source | 3,218,245Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 50,006Source | 30,816Source | 23,929Source | 16,217Source |
| Additional Paid in CapitalUSD | 85,632,303Source | 75,795,610Source | 68,911,778Source | 60,414,959Source |
| Retained Earnings (Accumulated Deficit)USD | -78,609,787Source | -75,004,413Source | -62,686,303Source | -50,826,812Source |
| Stockholders' Equity Attributable to ParentUSD | 7,072,522Source | 822,013Source | 6,249,404Source | 9,604,364Source |
| Liabilities and EquityUSD | 10,785,647Source | 5,369,940Source | 8,097,314Source | 12,822,609Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,303,083Source | 2,213,220Source | 1,792,626Source | 3,098,689Source |
| Operating Lease, Liability, CurrentUSD | 123,658Source | 65,768Source | — | — |
| Accounts Payable, CurrentUSD | 1,010,369Source | 1,029,206Source | 685,104Source | 927,662Source |
| Operating Lease, Liability, NoncurrentUSD | 143,148Source | 194,392Source | 55,284Source | 119,556Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,292,714Source | 1,184,014Source | 1,107,522Source | 715,839Source |
| Short-term InvestmentsUSD | — | — | — | 2,981,010Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 199,266Source | 118,620Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,264,608Source | 1,344,476Source | 1,105,457Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,088,169Source | 176,636Source | -33,237Source | -15,099Source |
| Increase (Decrease) in InventoriesUSD | -398,348Source | 908,467Source | 1,022,148Source | 606,251Source |
| Increase (Decrease) in Accounts PayableUSD | 239,983Source | 66,993Source | -247,189Source | 515,438Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -2,837,272Source | -11,011,840Source | -12,886,874Source | -7,519,534Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -81,742Source | -120,197Source | 2,649,964Source | -3,244,765Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 81,742Source | 120,197Source | 384,117Source | 275,226Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 124,617Source | 81,403Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 8,029,354Source | 7,269,586Source | 7,399,074Source | 12,023,282Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,570,382Source | 1,460,042Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,264,608Source | 1,344,476Source | 1,105,457Source | 947,212Source |
| Amortization of Debt Issuance CostsUSD | 192,647Source | 101,329Source | — | — |
| Amortization of Intangible AssetsUSD | 22,316Source | 22,315Source | 22,315Source | 22,315Source |
| DepreciationUSD | 239,363Source | 224,476Source | 176,951Source | 96,305Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -32,143Source | — |
| General and Administrative ExpenseUSD | 5,848,303Source | — | — | — |
| Inventory Write-downUSD | 10,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -3,605,374Source | -12,318,110Source | -11,859,491Source | -9,999,613Source |
| Operating ExpensesUSD | 12,367,879Source | 12,966,876Source | 13,866,955Source | 11,908,843Source |
| Other Nonoperating Income (Expense)USD | — | 125,179Source | 95,759Source | — |
| Payments of Financing CostsUSD | — | 75,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | 5,033,906Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 9,097,692Source | 3,453,003Source | 1,952,441Source | 171,169Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,384,517Source | 7,901,695Source | 6,926,269Source | 6,979,416Source |
| Operating Income (Loss)USD | -4,226,473Source | -11,887,209Source | -11,955,250Source | -10,030,765Source |
| Other Nonoperating Income (Expense)USD | — | 125,179Source | 95,759Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -3,605,374Source | -12,318,110Source | -11,859,491Source | — |
| Net Income (Loss) Attributable to ParentUSD | -3,605,374Source | -12,318,110Source | -11,859,491Source | -9,999,613Source |
| Earnings Per Share, BasicUSD per share | -0.09Source | -0.46Source | -0.65Source | -0.63Source |
| Earnings Per Share, DilutedUSD per share | -0.09Source | -0.46Source | -0.65Source | -0.63Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 40,152,873Source | 26,762,392Source | 18,121,108Source | 15,998,567Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 40,152,873Source | 26,762,392Source | 18,121,108Source | 15,998,567Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 22,316Source | 22,315Source | 22,315Source | 22,315Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 261,679Source | 246,791Source | — | — |
| General and Administrative ExpenseUSD | 5,848,303Source | — | — | — |
| Gross ProfitUSD | 5,141,406Source | 1,079,667Source | 456,517Source | -70,794Source |
| Operating ExpensesUSD | 12,367,879Source | 12,966,876Source | 13,866,955Source | 11,908,843Source |
| Other IncomeUSD | — | — | — | 31,152Source |
| Research and Development ExpenseUSD | 4,983,362Source | 5,065,181Source | 6,940,686Source | 4,929,427Source |
| Selling ExpenseUSD | 703.57Source | — | — | — |
Filing attachments
ea030757701ex99-1.htm · 8-K · 2026-10-05
Exhibit 99.1 NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn. - October 5, 2026 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treat…
Read attachment ↗ea030353001ex99-1.htm · 8-K · 2026-08-27
EX-99.1 2 ea030353001ex99-1.htm PRESS RELEASE, DATED AUGUST 27, 2026 Exhibit 99.1 NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in the Current Fiscal Quarter EDEN PRAIRIE, Minn. - August 27, 2026 - NeuroOne Medical Techno…
Read attachment ↗ea030178701ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ea030178701ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year Received ISO 13485 Certification Ahead of Schedule; International…
Read attachment ↗ea029192501ex99-1.htm · 8-K · 2026-05-22
EX-99.1 2 ea029192501ex99-1.htm PRESS RELEASE, DATED MAY 22, 2026 Exhibit 99.1 NeuroOne® Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026 Ongoing Business Not Affected, Company Reaffirms Product Revenue Guidance of at Least $10.5 Million for Fiscal Year 2026 Customer Order Modification at Quarter-End Resulted in Revenue Overstatement of Approximately $0.5 Million and Net Loss Understatement of Approximately $0.3 Million; No Prior Periods Im…
Read attachment ↗ea029009401ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ea029009401ex99-1.htm PRESS RELEASE, DATED MAY 12, 2026 Exhibit 99.1 NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update Product Revenue of $2.4 Million up 72% Year Over Year Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free* Management to Host Conference Call Today at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., May 12, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“Neur…
Read attachment ↗ea027713101ex99-1_neuroone.htm · 8-K · 2026-02-17
EX-99.1 2 ea027713101ex99-1_neuroone.htm PRESS RELEASE, DATED FEBRUARY 17, 2026 Exhibit 99.1 NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026 Nearly 50% of all Ablations Since OneRF ® Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with All Patients Reportedly Pain Free* Ma…
Read attachment ↗